From GlobeNewswire: 2025-05-08 18:00:00

Turnstone Biologics Corp. reported financial results for Q1 2025, with $21.9 million in cash, cash equivalents, and short-term investments. They discontinued TIDAL-01 clinical studies in January 2025 and moved to Nasdaq Capital Market in March 2025. Net loss for Q1 2025 was $11.8 million, down from $19.6 million in Q1 2024. Strategic alternatives are being explored.



Read more at GlobeNewswire:: Turnstone Biologics Corp. Reports First Quarter 2025